EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway

Koji Nishikawa, Teh-Wei Wang, Satoshi Kawakami, Shota Tanimoto, Kiyoshi Yamaguchi, Taketomo Kido, Masamichi Kimura, Tsunekazu Hishima, Yuki T Okamura, Satotaka Omori, Takumi Iritani, Toshikaze Chiba und 12 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202510562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Koji Nishikawa und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatocytes, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, MEXT/Japan Society for the Promotion of Science KAKENHI, Princess Takamatsu Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As organs undergo the process of aging, they exhibit signs of progressive fibrosis, a hallmark of aging that is observed in various organs, including the liver, kidneys, and lungs. Liver fibrosis is a particularly deleterious outcome of the healing processes that occur during the repair of chronic liver injury. It is widely accepted that the majority of these injuries are initially triggered by hepatocytes. Indeed, elderly patients have been shown to be more prone to developing liver fibrosis following hepatic injury. However, the mechanisms by which aging promotes fibrotic processes remain to be elucidated. The preceding observation, indicating a robust correlation between the severity of fibrosis in human cirrhotic patients and the population of hepatocytes expressing elevated levels of p16 Ink4a (p16 h ), proposes that p16 h hepatocytes might serve as initiators of fibrogenic processes in response to liver injury. In this study, we employed a CCl 4 ‐induced hepatitis model to promote a fibrogenic process and observed the accumulation of p16 h hepatocytes in zone 3. These p16 h cells manifest numerous senescent characteristics, and their accumulation has been strongly correlated with the severity of liver fibrosis. Selective elimination of p16 h hepatocytes has been shown to ameliorate CCl 4 ‐induced liver fibrosis, presumably through the suppression of hepatic stellate cell activation. Single‐cell transcriptomic analysis revealed that murine and human hepatocytes up‐regulated Ctf1 or Lif, the ligands of the LIFR signaling pathway. The administration of LIFR ligands has been demonstrated to enhance the phosphorylation of STAT3, and the LIFR inhibitor rescued the fibrogenic phenotype in hepatic stellate cells induced by secreted factors from senescent hepatocytes. This finding offers potential therapeutic insights for the management of liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisHepatocytesCyclin-Dependent Kinase Inhibitor p16AnimalsMiceSignal TransductionMaleHumansDisease Models, AnimalCellular SenescenceMice, Inbred C57BL

Stichwörter der Autor:innen

LIFR pathwaycellular senescenceliver fibrosis

Substanzen

Cyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Project Division of Generative AI Utilization Aging Cells, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
  • Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

ORCID-Profile: Makoto Nakanishi

Förderung

  • Japan Agency for Medical Research and Development
  • MEXT/Japan Society for the Promotion of Science KAKENHI
  • Princess Takamatsu Cancer Research Fund

Zitieren

APA

Nishikawa, K., Wang, T. W., Kawakami, S., Tanimoto, S., Yamaguchi, K., Kido, T., Kimura, M., Hishima, T., Okamura, Y. T., Omori, S., Iritani, T., Chiba, T., Jimbo, T., Katano, M., Kamataki, K., Yokoyama, R., Shimizu, E., Kimura, K., Yamzaki, S., …, & Nakanishi, M. (2026). p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway. Advanced Science. https://doi.org/10.1002/advs.202510562

Vancouver

Nishikawa K, Wang TW, Kawakami S, Tanimoto S, Yamaguchi K, Kido T, et al. p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway. Advanced Science. 2026. doi:10.1002/advs.202510562

BibTeX
@article{Nishikawa2026,
  author = {Nishikawa, Koji and Wang, Teh-Wei and Kawakami, Satoshi and Tanimoto, Shota and Yamaguchi, Kiyoshi and Kido, Taketomo and Kimura, Masamichi and Hishima, Tsunekazu and Okamura, Yuki T and Omori, Satotaka and Iritani, Takumi and Chiba, Toshikaze and Jimbo, Takehiro and Katano, Michio and Kamataki, Kansuporn and Yokoyama, Ryoichi and Shimizu, Eigo and Kimura, Kiminori and Yamzaki, Satoshi and Imoto, Seiya and Furukawa, Yoichi and Miyajima, Atsushi and Johmura, Yoshikazu and Nakanishi, Makoto},
  title = {p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202510562}
}
Kostenlos starten →